Empowered Funds
GANX icon

Empowered Funds’s Gain Therapeutics GANX Stock Holding History

Empowered Funds’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$90.4K Buy
+52,238
New +$95.3K ﹤0.01% 2427

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
PCM
Potomac Capital Management New York $129M AUM 50.83% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $273B AUM 15.34% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $45.2B AUM 20.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Empowered Funds's GANX Position: Q3 2026 in Review

Empowered Funds opened a new position in Gain Therapeutics (GANX) in Q3 2026: 52,238 shares worth $90.4K. The stake represents ﹤0.01% of the portfolio and ranks #2427 among its holdings.

38 funds tracked by Wall St. Rank hold GANX as of Q3 2026.

  • Empowered Funds held 52,238 shares of Gain Therapeutics worth $90.4K as of Q3 2026.
  • Gain Therapeutics was a new Empowered Funds position in Q3 2026.
  • Gain Therapeutics made up ﹤0.01% of Empowered Funds's portfolio in Q3 2026, its #2427 holding.
  • 38 funds tracked by Wall St. Rank held Gain Therapeutics as of Q3 2026.

Based on Empowered Funds's 13F filing for Q3 2026, filed 13 Nov 2026.